PMID- 18387077
OWN - NLM
STAT- MEDLINE
DCOM- 20080716
LR  - 20220331
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Print)
IS  - 0742-3071 (Linking)
VI  - 25
IP  - 4
DP  - 2008 Apr
TI  - Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 
      is a predictor of wound healing.
PG  - 419-26
LID - 10.1111/j.1464-5491.2008.02414.x [doi]
AB  - AIMS: Matrix metalloproteinases (MMPs) play a major role in wound healing: they 
      can degrade all components of the extracellular matrix. In diabetic foot ulcers 
      there is an excess of MMPs and a decrease of the tissue inhibitors of MMPs 
      (TIMPs). This imbalance is probably one cause of impaired healing. However, 
      little is known about changes in MMPs during wound healing. METHODS: Sixteen 
      patients with neuropathic diabetic foot ulcers participated. Wound fluid was 
      collected regularly during the 12-week follow-up period, for measurement of 
      MMP-1, MMP-2, MMP-8, MMP-9 and TIMP-1. Results were analysed by the degree of 
      wound healing: good healers (defined by a reduction of at least 82% in initial 
      wound surface at 4 weeks) and poor healers (reduction of less than 82% in wound 
      surface at 4 weeks). RESULTS: In good healers, levels of MMP-8 and -9 secreted by 
      inflammatory cells decreased earlier. The initial levels of MMP-1 were similar in 
      good and poor healers (P = 0.1) but rose significantly at week 2 in good healers 
      (P = 0.039). There was a significant correlation between a high ratio of 
      MMP-1/TIMP-1 and good healing (r = 0.65, P = 0.008). Receiver Operator Curve 
      (ROC) analysis showed that an MMP-1/TIMP-1 ratio of 0.39 best predicted wound 
      healing (sensitivity = 71%, specificity = 87.5%). CONCLUSIONS: A high level of 
      MMP-1 seems essential to wound healing, while an excess of MMP-8 and -9 is 
      deleterious, and could be a target for new topical treatments. The MMP-1/TIMP-1 
      ratio is a predictor of wound healing in diabetic foot ulcers.
FAU - Muller, M
AU  - Muller M
AD  - Department of Nephrology and Endocrinology, University Hospital, Grenoble, 
      France.
FAU - Trocme, C
AU  - Trocme C
FAU - Lardy, B
AU  - Lardy B
FAU - Morel, F
AU  - Morel F
FAU - Halimi, S
AU  - Halimi S
FAU - Benhamou, P Y
AU  - Benhamou PY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Body Fluids/enzymology
MH  - Diabetes Mellitus, Type 2/*enzymology
MH  - Diabetic Foot/*enzymology/physiopathology
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Extracellular Matrix/enzymology
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 1/*metabolism
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Tissue Inhibitor of Metalloproteinase-1/*metabolism
MH  - Treatment Outcome
MH  - Wound Healing/*physiology
PMC - PMC2326726
EDAT- 2008/04/05 09:00
MHDA- 2008/07/17 09:00
PMCR- 2008/04/22
CRDT- 2008/04/05 09:00
PHST- 2008/04/05 09:00 [pubmed]
PHST- 2008/07/17 09:00 [medline]
PHST- 2008/04/05 09:00 [entrez]
PHST- 2008/04/22 00:00 [pmc-release]
AID - DME2414 [pii]
AID - 10.1111/j.1464-5491.2008.02414.x [doi]
PST - ppublish
SO  - Diabet Med. 2008 Apr;25(4):419-26. doi: 10.1111/j.1464-5491.2008.02414.x.